The DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index.
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial
Open accessAbstract
Background Patients with peripheral artery disease have an increased risk of cardiovascular morbidity and mortality. Antiplatelet agents are widely used to reduce these complications.Methods This was a multicentre, double-blind, randomised placebo-controlled trial for which patients were recruited at 602 hospitals, clinics, or community practices from 33 countries across six continents. Eligible patients had a history of peripheral artery disease of the lower extremities (previous peripheral bypass surgery or angioplasty, limb or foot amputation, intermittent claudication with objective evidence of peripheral artery disease), of the carotid arteries (previous carotid artery revascularisation or asymptomatic carotid artery stenosis of at least 50%), or coronary artery disease with an ankle-brachial index of less than 0·90. After a 30-day run-in period, patients were randomly assigned (1:1:1) to receive oral rivaroxaban (2·5 mg twice a day) plus aspirin (100 mg once a day), rivaroxaban twice a day (5 mg with aspirin placebo once a day), or to aspirin once a day (100 mg and rivaroxaban placebo twice a day). Randomisation was computer generated. Each treatment group was double dummy, and the patient, investigators, and central study staff were masked to treatment allocation. The primary outcome was cardiovascular death, myocardial infarction or stroke; the primary peripheral artery disease outcome was major adverse limb events including major amputation. This trial is registered with ClinicalTrials.gov, number NCT01776424, and is closed to new participants.Findings Between March 12, 2013, and May 10, 2016, we enrolled 7470 patients with peripheral artery disease from 558 centres. The combination of rivaroxaban plus aspirin compared with aspirin alone reduced the composite endpoint of cardiovascular death, myocardial infarction, or stroke (126 [5%] of 2492 vs 174 [7%] of 2504; hazard ratio [HR] 0·72, 95% CI 0·57-0·90, p=0·0047), and major adverse limb events including major amputation (32 [1%] vs 60 [2%]; HR 0·54 95% CI 0·35-0·82, p=0·0037). Rivaroxaban 5 mg twice a day compared with aspirin alone did not significantly reduce the composite endpoint (149 [6%] of 2474 vs 174 [7%] of 2504; HR 0·86, 95% CI 0·69-1·08, p=0·19), but reduced major adverse limb events including major amputation (40 [2%] vs 60 [2%]; HR 0·67, 95% CI 0·45-1·00, p=0·05). The median duration of treatment was 21 months. The use of the rivaroxaban plus aspirin combination increased major bleeding compared with the aspirin alone group (77 [3%] of 2492 vs 48 [2%] of 2504; HR 1·61, 95% CI 1·12-2·31, p=0·0089), which was mainly gastrointestinal. Similarly, major bleeding occurred in 79 (3%) of 2474 patients with rivaroxaban 5 mg, and in 48 (2%) of 2504 in the aspirin alone group (HR 1·68, 95% CI 1·17-2·40; p=0·0043).Interpretation Low-dose rivaroxaban taken twice a day plus aspirin once a day reduced major adverse cardiovascular and limb events when compared with aspirin alone. Although major bleeding was increased, fatal or critical organ bleeding was not. This combination therapy represents an important advance in the management of patients with peripheral artery disease. Rivaroxaban alone did not significantly reduce major adverse cardiovascular events compared with asprin alone, but reduced major adverse limb events and increased major bleeding.Funding Bayer AG.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“A study shared that low-dose rivaroxaban with aspirin reduced major adverse cardiovascular and limb events compared with aspirin alone without significantly increasing major bleeding [82].”
From Revascularization Strategies for Acute and Chronic Mesenteric Ischemia: A Narrative Review (2024) · cites this paper as [82]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“There was an associated increased risk of bleeding with rivaroxaban, although no significant excess in fatal bleeding was noted.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [58]
In the citing paper
“a review of 56 studies including patients with diabetes suggested higher limbsalvage rates after revascularization (78-85% at 1 year) compared with conservative management.768”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [768]
In the citing paper
“The risk of major adverse cardiovascular events (MACEs) was significantly lower with the combination of rivaroxaban plus aspirin compared with either aspirin alone or rivaroxaban alone.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [58]
In the citing paper
“The ischemic benefits of rivaroxaban were consistent in the subgroup with diabetes mellitus, suggesting that low-dose anticoagulation added to antiplatelet therapy may be another option for secondary prevention in patients with T2DM and stable CAD.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [58]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Self-citationClopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events
Bhatt, D. L., Fox, K. A. A., Hacke, W., Berger, P. B., Black, H. R., Boden, W. E., Cacoub, P., Cohen, E. A., Creager, M. A., Easton, J. D., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060989 · Cited by 2,819
Self-citationRivaroxaban with or without aspirin in stable cardiovascular disease
Eikelboom, J. W., Connolly, S. J., Bosch, J., Dagenais, G. R., Hart, R. G., Shestakovska, O., Diaz, R., Alings, M., Lonn, E. M., Anand, S. S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709118 · Cited by 2,438
Self-citationRivaroxaban in Patients with a Recent Acute Coronary Syndrome
Mega, J. L., Braunwald, E., Wiviott, S. D., Bassand, J., Bhatt, D. L., Bode, C., Burton, P. B. J., Cohen, M. C., Cook‐Bruns, N., Fox, K. A. A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1112277 · Cited by 1,923
Self-citationESC Guidelines on the diagnosis and treatment of peripheral artery diseases
Endorsed by: the European Stroke Organisation (ESO), Authors/Task Force Members, Tendera, M., Aboyans, V., Bartelink, M.-L., Baumgartner, I., Clément, D., Collet, J.-P., Cremonesi, A., De Carlo, M., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr211 · Cited by 1,506
Self-citationRivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
Eriksson, B. I., Borris, L. C., Friedman, R. J., Haas, S., Huisman, M. V., Kakkar, A. K., Bandel, T. J., Beckmann, H., Muehlhofer, E., Misselwitz, F., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800374 · Cited by 1,433
Self-citationOne-year cardiovascular event rates in outpatients with atherothrombosis
Steg, P. G., Bhatt, D. L., Wilson, P. W. F., D’Agostino, R., Ohman, E. M., Röther, J., Liau, C.-S., Hirsch, A. T., Mas, J.-L., Ikeda, Y., et al. (2007) · JAMA · doi:10.1001/jama.297.11.1197 · Cited by 1,382
Self-citationGerhard‐Herman, M. D., Gornik, H. L., Barrett, C., Barshes, N. R., Corriere, M. A., Drachman, D. E., Fleisher, L. A., Fowkes, F. G. R., Hamburg, N. M., Kinlay, S., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000471 · Cited by 1,048
Brott, T. G., Halperin, J. L., Abbara, S., Bacharach, J. M., Barr, J. D., Bush, R. L., Cates, C. U., Creager, M. A., Fowler, S. A., Friday, G. H., et al. (2011) · Circulation · doi:10.1161/cir.0b013e31820d8d78 · Cited by 801
Self-citationConnolly, S. J., Eikelboom, J. W., Bosch, J., Dagenais, G., Dyal, L., Lanas, F., Metsarinne, K., O'Donnell, M., Dans, A. L., Ha, J.-W., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32458-3 · Cited by 754
Self-citation
Research works printed but not linked: 2
- 1996, A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE), Lancet, 348, 329
- Connolly, 2017, Rivaroxaban in stable coronary disease, Lancet
Cited by
Sorted by citations
Items 101–200 of 877
Lower extremity artery disease in patients with type 2 diabetes
Buso, G., Aboyans, V., & Mazzolai, L. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319880044 · Cited by 48
“5mg combined with aspirin significantly decreased the occurrence of MACEs, lower limb ischaemia and major amputations compared with aspirin alone.(57) This pharmacological association may provide future therapeutic perspectives in diabetic patients with LEAD.”
BackgroundSelf-citationRivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction
Fox, K. A. A., Eikelboom, J. W., Shestakovska, O., Connolly, S. J., Metsarinne, K. P., & Yusuf, S. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.02.048 · Cited by 56
Self-citationParvar, S., Thiyagarajah, A., Nerlekar, N., King, P. M., & Nicholls, S. J. (2020) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2020.09.039 · Cited by 55
Martinelli, I., Abbattista, M., Bucciarelli, P., Tripodi, A., Artoni, A., Gianniello, F., Novembrino, C., & Peyvandi, F. (2018) · Haematologica · doi:10.3324/haematol.2017.185132 · Cited by 51
Bernatchez, J., Mayo, A. L., & Kayssi, A. (2021) · Seminars in Vascular Surgery · doi:10.1053/j.semvascsurg.2021.02.011 · Cited by 56
German, C. A., Baum, S. J., Ferdinand, K. C., Gulati, M., Polonsky, T. S., Toth, P. P., & Shapiro, M. D. (2022) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2022.100432 · Cited by 55
Ge, J., Wei-hu, F., Zhou, J., Shi, H., Ji, F., Wu, Y., Zhao, Y., Qian, J., Jin, Y., Liu, Y., et al. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001257 · Cited by 48
“The inclusion criterion for coronary stenosis was ≥50% in one or more coronary arteries compared with ≥50% in two or more coronary arteries in the COMPASS trial.([26]) Other trials, such as the Intravascular Cooling in the Treatment of Stroke trial, reported MACE rates of > 20%, but they enrolled patients who were at…”
BackgroundResultSelf-citationBleeding and New Cancer Diagnosis in Patients With Atherosclerosis
Eikelboom, J. W., Connolly, S. J., Bosch, J., Shestakovska, O., Aboyans, V., Alings, M., Anand, S. S., Avezum, Á., Berkowitz, S. D., Bhatt, D. L., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.041949 · Cited by 48
Self-citationEikelboom, J. W., Bosch, J., Connolly, S. J., Shestakovska, O., Dagenais, G. R., Hart, R. G., Leong, D. P., O'Donnell, M. J., Fox, K. A. A., Bhatt, D. L., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.07.065 · Cited by 46
Self-citationMahé, G., Böge, G., Bura-Rivière, A., Chakfé, N., Constans, J., Gouëffic, Y., Lacroix, P., Hello, C. L., Pernod, G., Pérez‐Martin, A., et al. (2020) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2020.11.011 · Cited by 53
Martelli, E., Enea, I., Zamboni, M., Federici, M., Bracale, U. M., Sangiorgi, G., Martelli, A. R., Messina, T., & Settembrini, A. M. (2023) · Diagnostics · doi:10.3390/diagnostics13142356 · Cited by 44
“5 mg bid) rivaroxaban (one of the four oral anticoagulants non-vitamin K antagonist) plus acetylsalicylic acid (100 mg qd) has been shown to reduce the risk of MACE and MALE compared to low-dose aspirin alone in symptomatic LEAD patients [64,65].”
BackgroundIncidence and Factors Associated With Major Amputation in Patients With Peripheral Artery Disease
Long, C. A., Mulder, H. S., Fowkes, F. G. R., Baumgärtner, I., Berger, J. S., Katona, B. G., Mahaffey, K. W., Norgren, L., Blomster, J., Rockhold, F. W., et al. (2020) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.119.006399 · Cited by 45
Katz, D. H., & Gavin, M. C. (2019) · Annals of Internal Medicine · doi:10.7326/aitc201908060 · Cited by 49
Anand, S. S., Hiatt, W. R., Dyal, L., Bauersachs, R. M., Berkowitz, S. D., Branch, K. R., Debus, S. E., Fox, K. A. A., Liang, Y., Muehlhofer, E., et al. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab128 · Cited by 44
“Both trials received central and local research ethics board approvals and adjudicated primary endpoint components and have been previously published.(8,9) Briefly, COMPASS was a multicentre, double-blind, randomized, placebocontrolled trial that enrolled 27 395 patients with coronary artery disease (CAD) and/or PAD,…”
MethodSelf-citationSiegler, J. E., Thon, J. M., Woo, J. H., Do, D., Messe, S. R., & Cucchiara, B. L. (2019) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2019.07.005 · Cited by 41
Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease
Coppens, M., Weitz, J. I., & Eikelboom, J. W. (2019) · Circulation Research · doi:10.1161/circresaha.118.313141 · Cited by 42
Self-citationPeripheral artery disease and outcomes in patients with acute myocardial infarction
Attar, R., Wester, A., Koul, S. M., Eggert, S., & Andell, P. (2019) · Open Heart · doi:10.1136/openhrt-2018-001004 · Cited by 43
“Newer studies have implicated that antithrombotic medications, such as ticagrelor and clopidogrel, could be advantageous as supplementing therapies in reducing the risk of cardiovascular events in patients with PAD.(10) 13 14 The COMPASS PAD trial(10) concluded, for the first time, the use of rivaroxaban (2.”
BackgroundBaker, W. L., Beyer‐Westendorf, J., Bunz, T. J., Eriksson, D., Meinecke, A., Sood, N. A., & Coleman, C. I. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13787 · Cited by 42
“08).(19) The present study showed a similar reduction in MALE and major limb amputation risk with therapeutic dosages of rivaroxaban compared with warfarin in an NVAF population with T2D.”
ResultA Practical Review of the Emerging Direct Anticoagulants, Laboratory Monitoring, and Reversal Agents
Joppa, S., Salciccioli, J. D., Adamski, J., Patel, S. I., Wysokiński, W. E., McBane, R. D., Al‐Saffar, F., Esser, H., & Shamoun, F. E. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7020029 · Cited by 44
“There was more bleeding in the group with rivaroxaban plus aspirin and rivaroxaban alone versus aspirin [99].”
BackgroundAssessment and management of peripheral arterial disease: what every cardiologist should know
Tran, B. G. (2021) · Heart · doi:10.1136/heartjnl-2019-316164 · Cited by 42
Qamar, A., Morrow, D. A., Creager, M. A., Scirica, B. M., Olin, J. W., Beckman, J. A., Murphy, S. A., & Bonaca, M. P. (2020) · Vascular Medicine · doi:10.1177/1358863x19892690 · Cited by 40
Chan, Y., Lee, H., Li, P., Liu, J., Chao, T., Wu, L., Chang, S., Yeh, Y., Kuo, C.-T., See, L., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01043-2 · Cited by 41
Chatterjee, M., Ehrenberg, A., Toska, L. M., Metz, L. M., Klier, M., Krüger, I., Reusswig, F., & Elvers, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21217906 · Cited by 40
Changes in the landscape of anticoagulation: a focus on direct oral anticoagulants
Ageno, W., Caramelli, B., Donadini, M. P., Girardi, L., & Riva, N. (2024) · The Lancet Haematology · doi:10.1016/s2352-3026(24)00281-3 · Cited by 48
Vogel, S., Murthy, P., Cui, X. D., Lotze, M. T., Zeh, H. J., & Sachdev, U. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.11.125 · Cited by 38
Preoperative evaluation and perioperative management of patients undergoing major vascular surgery
Lee, C., Columbo, J. A., Stone, D. H., Creager, M. A., & Henkin, S. (2022) · Vascular Medicine · doi:10.1177/1358863x221122552 · Cited by 42
Barraclough, J. Y., Yu, J., Figtree, G. A., Perkovic, V., Heerspink, H. J. L., Neuen, B. L., Cannon, C. P., Mahaffey, K. W., Schutte, A. E., Neal, B., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14671 · Cited by 37
“However, the amputation finding in the CANVAS Program(14) has raised uncertainty about the benefit-to-risk ratio of canagliflozin in patients with PAD already at greater baseline risk of vascular and limb events.(20,21) Accordingly, we sought to define the proportional and absolute effects of canagliflozin versus plac…”
BackgroundNon-alcoholic fatty liver disease: a metabolic burden promoting atherosclerosis
Zhang, L., She, Z., Li, H., & Zhang, X. (2020) · Clinical Science · doi:10.1042/cs20200446 · Cited by 39
Zhao, T., Chen, Y., Wang, D., Wang, L., Dong, P., Zhao, S., Wang, C., Meng, Q., Sun, H., Liu, K., et al. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07129-z · Cited by 38
Self-citationMultidisciplinary Care for Critical Limb Ischemia: Current Gaps and Opportunities for Improvement
Armstrong, E. J., Alam, S., Henao, S., Lee, A. C., DeRubertis, B. G., Montero-Baker, M. F., Mena, C. I., Cua, B., Palena, L. M., Kovach, R. C., et al. (2019) · Journal of Endovascular Therapy · doi:10.1177/1526602819826593 · Cited by 36
Vanassche, T., Verhamme, P. B., Anand, S. S., Shestakovska, O., Fox, K. A. A., Bhatt, D. L., Avezum, Á., Alings, M., Aboyans, V., Maggioni, A. P., et al. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319882154 · Cited by 40
Self-citationPeripheral vascular disease risk in diabetic individuals without coronary heart disease
Wilcox, T., Newman, J. D., Maldonado, T. S., Rockman, C. R., & Berger, J. S. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.04.026 · Cited by 38
Umbrella review and meta-analysis of antiplatelet therapy for peripheral artery disease
Ambler, G. K., Waldron, C.-A., Contractor, U. B., Hinchliffe, R. J., & Twine, C. P. (2020) · Journal of British Surgery · doi:10.1002/bjs.11384 · Cited by 35
“COMPASS showed that the combination of rivaroxaban and aspirin prevented 18 major adverse cardiovascular events per 1000 patients, while causing 12 additional major bleeds when compared to aspirin alone.(10) The effect size is again relatively small for an expensive on-patent drug; by way of comparison, CAPRIE showed…”
BackgroundResultWeissler, E. H., Jones, W. S., Désormais, I., Debus, S., Mazzolai, L., Espinola–Klein, C., Nikol, S., Nehler, M. R., Sillesen, H. H., Aboyans, V., et al. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.11.001 · Cited by 35
Self-citationCause of Death Among Patients With Peripheral Artery Disease
Kochar, A., Mulder, H. S., Rockhold, F. W., Baumgärtner, I., Berger, J. S., Blomster, J., Fowkes, F. G. R., Katona, B. G., Lópes, R. D., Al‐Khalidi, H. R., et al. (2020) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.120.006550 · Cited by 37
Update on prevention of diabetic foot ulcer
Miranda, C., ROS, R. D., & Marfella, R. (2021) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad.2021.107817 · Cited by 47
Chuter, V., Quigley, F., Tosenovsky, P., Ritter, J. C., Charles, J., Cheney, J., Fitridge, R., & Australian Diabetes‐related Foot Disease Guidelines & Pathways Project (2022) · Journal of Foot and Ankle Research · doi:10.1186/s13047-022-00550-7 · Cited by 37
“The panel agreed with the IWGDF that there is no clear evidence in favour of one antiplatelet agent over another, although the panel also agreed that their use individually and in combination is likely to reduce major lower limb events and contribute to a reduction in 5 year mortality [62, 63].”
Ueng, K., Chiang, C., Chao, T., Wu, Y., Lee, W.-L., Li, Y., Ting, K.-H., Su, C.-H., Lin, H., Su, T., et al. (2023) · PubMed Central · doi:10.6515/acs.202301_39(1).20221103a · Cited by 34
Willems, L. H., Maas, D. P. M. S. M., Kramers, K., Reijnen, M. M. P. J., Riksen, N. P., Cate, H. T., van der Vijver-Coppen, R. J., de Borst, G. J., Mees, B., Zeebregts, C. J., et al. (2022) · Drugs · doi:10.1007/s40265-022-01756-6 · Cited by 37
“Recently, two large randomized controlled trials (RCTs), respectively, including patients with symptomatic PAD or patients undergoing a peripheral vascular intervention (endovascular or surgical), demonstrated superiority of ASA plus low-dose rivaroxaban over ASA monotherapy [16, 17].”
BackgroundInfluentialCauses and Secondary Prevention of Acute Ischemic Stroke in Adults
Jensen, M., & Thomalla, G. (2019) · Hämostaseologie · doi:10.1055/s-0039-1700502 · Cited by 33
Weitz, J. I., Angiolillo, D. J., Geisler, T., & Heitmeier, S. (2020) · Thrombosis and Haemostasis · doi:10.1055/s-0040-1713376 · Cited by 33
Kim, B. S., Auerbach, D. S., Sadhra, H., Godwin, M., Bhandari, R., Ling, F. S. K., Mohan, A. M., Yule, D. I., Wagner, L. E., Rich, D. Q., et al. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.315033 · Cited by 32
Genetic Determinants of Peripheral Artery Disease
Klarin, D. M., Tsao, P. S., & Damrauer, S. M. (2021) · Circulation Research · doi:10.1161/circresaha.121.318327 · Cited by 33
Fox, K. A. A., Aboyans, V., Debus, E. S., Zeymer, U., Cowie, M., Patel, M. R., Welsh, R. C., Bosch, J., Gay, A., Vogtländer, K., et al. (2022) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvac028 · Cited by 33
Self-citationSmolderen, K. G. E., Alabi, O., Collins, T. C., Dennis, B., Goodney, P. P., Mena‐Hurtado, C., Spertus, J. A., & Decker, C. (2022) · Circulation · doi:10.1161/cir.0000000000001105 · Cited by 34
“Distinctions among PROs, PROMs, and PRO-PMs.”
BackgroundMethodInfluentialEmerging agents for the treatment and prevention of stroke: progress in clinical trials
Safouris, A., Magoufis, G., & Tsivgoulis, G. K. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1985463 · Cited by 32
Extra-Cranial Carotid Artery Stenosis: An Objective Analysis of the Available Evidence
Abbott, A. L. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.739999 · Cited by 31
Association of Lipoprotein(a) Levels With Incidence of Major Adverse Limb Events
Guédon, A. F., de Fréminville, J.-B., Mirault, T., Mohamedi, N., Rance, B., Fournier, N., Paul, J., Messas, E., & Goudot, G. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.45720 · Cited by 32
Self-citationPoor attainment of lipid targets in patients with symptomatic peripheral artery disease
Dopheide, J. F., Papac, L., Schindewolf, M., Baumgärtner, I., & Drexel, H. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.02.013 · Cited by 29
Acute Limb Ischemia Therapies: When and How to Treat Endovascularly
Hage, A. N., McDevitt, J. L., Chick, J. F. B., & Vadlamudi, V. (2018) · Seminars in Interventional Radiology · doi:10.1055/s-0038-1676321 · Cited by 32
Conte, M. S., Aulivola, B., Barshes, N. R., Bertges, D. J., Corriere, M. A., Murad, M. H., Powell, R. J., Reed, A. B., Robinson, W. P., & Simons, J. P. (2025) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2025.04.041 · Cited by 33
Ding, Y., Li, X., Zhou, M., Cai, L., Tang, H., Xie, T., Shi, Z., & Fu, W. (2020) · Vascular Pharmacology · doi:10.1016/j.vph.2020.106818 · Cited by 29
Advances in Recurrent Stroke Prevention: Focus on Antithrombotic Therapies
Grory, B. M., Yaghi, S. R., Cordonnier, C., Sposato, L. A., Romano, J. G., & Chaturvedi, S. (2022) · Circulation Research · doi:10.1161/circresaha.121.319947 · Cited by 29
Fox, K. A. A., Eikelboom, J. W., Anand, S. S., Bhatt, D. L., Bosch, J., Connolly, S. J., Harrington, R. A., Steg, P. G., & Yusuf, S. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy347 · Cited by 28
Self-citationHuang, W., Singer, D. E., Wu, Y., Chiang, C., Weng, H., Lee, M., & Ovbiagele, B. I. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.2215 · Cited by 29
Self-citationFurtado, R. H. M., & Giugliano, R. P. (2020) · Cardiology and Therapy · doi:10.1007/s40119-020-00163-w · Cited by 29
Olesen, K. K. W., Gyldenkerne, C., Thim, T., Thomsen, R. W., & Mæng, M. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001803 · Cited by 32
Duceppe, E., Yusuf, S., Tandon, V., Rodseth, R. N., Biccard, B. M., Xavier, D., Szczeklik, W., Meyhoff, C. S., Franzosi, M. G., Vincent, J., et al. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2018.01.020 · Cited by 27
Self-citationHeiß, C., Olinic, D.-M., Belch, J. J. F., Brodmann, M., Mazzolai, L., Stanek, A., Maďarič, J., Krentz, A. J., Schlager, O., Lichtenberg, M. K. W., et al. (2022) · VASA · doi:10.1024/0301-1526/a000998 · Cited by 29
Elevated lipoprotein (a) levels and risk of peripheral artery disease outcomes: A systematic review
Masson, W. M., Lobo, M., Barbagelata, L., Molinero, G., Bluro, I. M., & Nogueira, J. P. (2022) · Vascular Medicine · doi:10.1177/1358863x221091320 · Cited by 29
Piechocki, M., Przewłocki, T., Pieniążek, P., Trystuła, M., Podolec, J., & Kabłak-Ziembicka, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051508 · Cited by 29
“…vascular dose (2.5 mg twice daily) in combination with ASA (100 mg once daily) in patients with clinically stable ICAS or PAD significantly reduced the incidence of MACCEs, stroke, and MALEs, including amputations, compared with ASA alone, but at the expense of increased major bleeding [105–107].”
BackgroundInfluentialBhatt, D. L., Fox, K. M., Harrington, R. A., Leiter, L. A., Mehta, S. R., Simon, T., Andersson, M., Himmelmänn, A., Ridderstråle, W., Held, C., et al. (2019) · Clinical Cardiology · doi:10.1002/clc.23164 · Cited by 25
Self-citationCarlo, M. D., Minno, G. D., Sayre, T., Fazeli, M. S., Siliman, G., & Cimminiello, C. (2020) · Current Vascular Pharmacology · doi:10.2174/1570161118666200820141131 · Cited by 27
Peripheral arterial disease and intermittent claudication in coronary heart disease patients
Reiner, Ž., SUTTER, J. D., Rydén, L., Mirrakhimov, E. M., Вачиковна, П. Н., Долженко, М. М., Fras, Z., Kotseva, K., Wood, D., & Bacquer, D. D. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.09.004 · Cited by 29
Evidence-Based Recommendations for Medical Management of Peripheral Artery Disease
Golledge, J., & Drovandi, A. D. (2021) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.62778 · Cited by 27
Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease
Belch, J. J. F., Brodmann, M., Baumgärtner, I., Binder, C. J., Casula, M., Heiß, C., Kahan, T., Parini, P., Poredoš, P., Catapano, A. L., et al. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.09.022 · Cited by 27
Antithrombotic Therapy for Aortic Aneurysms: A Systematic Review and Meta-Analysis
Wong, K., Zlatanović, P., Bosanquet, D. C., Saratzis, A. N., Kakkos, S. K., Aboyans, V., & Twine, C. P. (2022) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2022.07.008 · Cited by 26
Self-citationMackman, N., Spronk, H. M. H., Stouffer, G. A., & Cate, H. T. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.310048 · Cited by 29
Jansen, S. J., de Borst, G. J., Hinchliffe, R. J., & Teraa, M. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.09.021 · Cited by 28
Self-citation5 Conservative treatment for PAD – Risk factor management
Frank, U., Nikol, S., & Belch, J. J. F. (2019) · VASA · doi:10.1024/0301-1526/a000835 · Cited by 27
Self-citationBradaric, C., Koppara, T., Müller, A. M., Haller, B., Ott, I., Cassese, S., Fusaro, M., Kastrati, A., Laugwitz, K., & Ibrahim, T. (2019) · EuroIntervention · doi:10.4244/eij-d-19-00187 · Cited by 25
Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease
Belch, J. J. F., Brodmann, M., Baumgärtner, I., Binder, C. J., Casula, M., Heiß, C., Kahan, T., Parini, P., Poredoš, P., Catapano, A. L., et al. (2021) · VASA · doi:10.1024/0301-1526/a000969 · Cited by 26
“Inhibition of thrombin generation with a low dose Factor Xa inhibitor added to antiplatelet therapy can reduce ischaemic risk, as demonstrated by the COMPASS trial in patients with stable CAD or PAD [69, 78].”
BackgroundWhen and How to Combine Antiplatelet and Anticoagulant Drugs?
Espinola–Klein, C. (2022) · Hämostaseologie · doi:10.1055/a-1724-4922 · Cited by 30
Smolderen, K. G. E., Romain, G., Provance, J., Scierka, L. E., Mao, J., Goodney, P. P., Henke, P. K., Sedrakyan, A., & Mena‐Hurtado, C. (2023) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2022.09.022 · Cited by 26
Poorthuis, M. H. F., Solomon, Y., Herings, R. A. R., Visseren, F. L. J., Kappelle, L. J., Bots, M. L., Rissanen, I. L., & de Borst, G. J. (2023) · Stroke · doi:10.1161/strokeaha.122.041921 · Cited by 25
Zomer, E., Si, S., Hird, T. R., Liew, D., Owen, A. J., Tonkin, A., Reid, C. M., & Ademi, Z. (2018) · European Journal of Preventive Cardiology · doi:10.1177/2047487318817910 · Cited by 25
Lee, S., Koppensteiner, R., Kopp, C. W., & Gremmel, T. (2019) · Scientific Reports · doi:10.1038/s41598-019-54899-0 · Cited by 25
Liang, Y., Zhu, J., Liu, L., Anand, S. S., Connolly, S. J., Bosch, J., Guzik, T. J., O'Donnell, M. J., Dagenais, G. R., Fox, K. A. A., et al. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa100 · Cited by 26
Self-citationAntithrombotic Strategies for Patients With Peripheral Artery Disease
Bonaca, M. P., Barnes, G. D., Bauersachs, R. M., Bessada, Y., Conte, M. S., Dua, A., Hess, C. N., Serhal, M., Mena‐Hurtado, C., Weitz, J. I., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.06.027 · Cited by 24
Effect of coexisting vascular disease on long-term risk of recurrent events after TIA or stroke
Boulanger, M., Li, L., Lyons, S., Lovett, N. G., Kubiak, M. M., Silver, L. E., Touzé, E., Rothwell, P. M., Study, O. B. O. T. O. V., Study, O. B. O. T. O. V., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000007935 · Cited by 25
“subgroup of patients with carotid artery disease did benefit from combination treatment.(9) Moreover, the annual risk of stroke was <1% in the aspirin-alone group, which is lower than reported after TIA and ischemic stroke in routine practice,(10) particularly in patients with coexisting coronary or peripheral artery…”
Resultcollaborators, C. S., Wong, K., Bosanquet, D. C., Ambler, G. K., Qureshi, M. I., Hinchliffe, R. J., & Twine, C. P. (2019) · CVIR Endovascular · doi:10.1186/s42155-019-0079-8 · Cited by 24
“2016), and well publicised trials of direct oral anticoagulants for non-intervened peripheral arterial disease (Anand et al. 2018), and it has become even more confusing for peripheral endovascular practitioners.”
BackgroundContemporary Review of Antithrombotic Therapy in Peripheral Artery Disease
Hess, C. N., & Bonaca, M. P. (2020) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.120.009584 · Cited by 25
Bauersachs, R. M., Debus, E. S., Nehler, M. R., Huelsebeck, M., Balradj, J., Bowrin, K., & Brière, J. (2019) · Angiology · doi:10.1177/0003319719896477 · Cited by 23
“5 mg BID plus aspirin significantly reduced the risk of MACE by 28% and MALE and major amputation by 46%, and increased the risk of major bleeding by 61%, compared with aspirin alone.(30) Several characteristics associated with poorer prognosis in patients with PAD are listed in Table 2.”
BackgroundFox, K. A. A., Anand, S. S., Aboyans, V., Cowie, M., Debus, E. S., Zeymer, U., Monje, D., Vogtländer, K., Lawatscheck, R., & Gay, A. (2020) · American Heart Journal · doi:10.1016/j.ahj.2020.01.015 · Cited by 24
Self-citationEikelboom, J. W., Bosch, J., Connolly, S. J., Tyrwitt, J., Fox, K. A. A., Muehlhofer, E., Neumann, C., Tasto, C., Bangdiwala, S. I., Díaz, R., et al. (2022) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvac023 · Cited by 24
Self-citationConcomitant diabetes with atrial fibrillation and anticoagulation management considerations
Kreutz, R. H., Camm, A. J., & Rossing, P. R. (2020) · European Heart Journal Supplements · doi:10.1093/eurheartj/suaa182 · Cited by 22
“Given the limitation of non-randomized observations, this needed to be confirmed in a pre-specified subgroup of people with peripheral artery disease and diabetes in the Phase III COMPASS study which compared low-dose rivaroxabanþ aspirin to aspirin alone in 7470 participants with peripheral artery disease.(34) In the…”
BackgroundMethodGalli, M., Franchi, F., Rollini, F., Been, L. F., Jaoude, P. A., Rivas, A., Zhou, X., Jia, S., Maaliki, N., Lee, C. H., et al. (2022) · Thrombosis and Haemostasis · doi:10.1055/a-1730-8725 · Cited by 22
Self-citationMcClure, G. R., Kaplovitch, E., Narula, S., Bhagirath, V. C., & Anand, S. S. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1198-5 · Cited by 23
Self-citationEmery, C., Torreton, E., Brière, J., Evers, T., & Fagnani, F. (2020) · Journal of Medical Economics · doi:10.1080/13696998.2020.1715415 · Cited by 22
Gene Expression Signature in Patients With Symptomatic Peripheral Artery Disease
Newman, J. D., Cornwell, M., Zhou, H., Rockman, C. R., Heguy, A., Suárez, Y., Cheng, H. S., Feinberg, M. W., Hochman, J. S., Ruggles, K. V., et al. (2021) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.315857 · Cited by 21
Armario, P., Brotons, C., Elosúa, R., de Leciñana, M. A., Castro, A., Clarà, A. B. I., Cortés, O., Rodríguez, Á. D., Herranz, M., Justo, S., et al. (2021) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2021.02.001 · Cited by 20
Sun, X., Zhang, C., Ma, Y., He, Y., Zhang, X., & Wu, J. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02201-6 · Cited by 25
“…(Rivaroxaban 2.5 mg twice a day; Aspirin 100 mg once a day) improved the long-term patency rate of lower extremity artery disease after endovascular therapy, reduced the incidence of major limb adverse events and cardiovascular events, and did not increase the risk of fatal major bleeding [52–54].”
BackgroundInfluentialAntithrombotic Therapy in Peripheral Artery Disease
Jones, W. S., & Patel, M. R. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.021 · Cited by 22
“In a simultaneous presentation, the PAD cohort from COMPASS was equally effective (36).”
Lee, H., See, L., Li, P., Liu, J., Chao, T., Chang, S., Wu, L., Yeh, Y., Kuo, C.-T., Chan, Y., et al. (2019) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvz072 · Cited by 21
Hamann, G. F., Sander, D., Grau, A., & Röther, J. (2022) · DGNeurologie · doi:10.1007/s42451-022-00461-8 · Cited by 21
Managing thrombotic risk in patients with diabetes
Camm, A. J., Sabbour, H. M., Schnell, O., Summaria, F., & Verma, A. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01581-x · Cited by 24
“This relative risk reduction was consistent in patients with and without diabetes, along with a relative risk reduction in all-cause death and the composite of CV death, MI or stroke in both patient groups and a consistent rate of net clinical benefit outcomes (MI, stroke, CV death, fatal bleeding or symptomatic criti…”
ResultPreventing Major Amputations in Patients with Critical Limb Ischemia
Rudofker, E. W., Hogan, S. E., & Armstrong, E. J. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-1019-2 · Cited by 21
Rivaroxaban for the treatment of venous thromboembolism in pediatric patients
Cohen, O., Levy‐Mendelovich, S., & Ageno, W. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1823218 · Cited by 21
Cardiovascular Risk/Disease in Type 2 Diabetes Mellitus
Román, G., & Stoian, A. P. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.97422 · Cited by 26
Angraal, S., Hejjaji, V., Tang, Y., GOSCH, K. L., Patel, M. R., Heyligers, J. M. M., White, C. J., Nolthenius, R. T., Mena‐Hurtado, C., Aronow, H. D., et al. (2022) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.121.011506 · Cited by 21
Metadata
- Authors
- Anand, S. S., Bosch, J., Eikelboom, J. W., Connolly, S. J., Diaz, R., Widimsky, P., Aboyans, V., Alings, M., Kakkar, A. K., Keltai, K., Maggioni, A. P., Lewis, B. S., Störk, S., Zhu, J., Lopez-Jaramillo, P., O'Donnell, M., Commerford, P. J., Vinereanu, D., Pogosova, N., Ryden, L., Fox, K. A. A., Bhatt, D. L., Misselwitz, F., Varigos, J. D., Vanassche, T., Avezum, A. A., Chen, E., Branch, K., Leong, D. P., Bangdiwala, S. I., Hart, R. G., Yusuf, S., SALA, J., CARTASEGNA, L., VICO, M., HOMINAL, M. A., HASBANI, E., CACCAVO, A., ZAIDMAN, C., VOGEL, D., HRABAR, A., SCHYGIEL, P. O., CUNEO, C., LUQUEZ, H., MACKINNON, I. J., AHUAD GUERRERO, R. A., COSTABEL, J. P., BARTOLACCI, I. P., MONTANA, O., BARBIERI, M., GOMEZ VILAMAJO, O., GARCIA DURAN, R. O., SCHIAVI, L. B., GARRIDO, M., INGARAMO, A., BORDONAVA, A. P., PELAGAGGE, M. J., NOVARETTO, L., ALBISU DI GENNERO, J. P., IBANEZ SAGGIA, L. M., ALVAREZ, M., VITA, N. A., MACIN, S. M., DRAN, R. D., CARDONA, M., GUZMAN, L., SARJANOVICH, R. J., CUADRADO, J., NANI, S., LITVAK BRUNO, M. R., CHACON, C., MAFFEI, L. E., GRINFELD, D., VENSENTINI, N., MAJUL, C. R., LUCIARDI, H. L., GONZALEZ COLASO, P. D. C., FERRE PACORA, F. A., VAN DEN HEUVEL, P., VERHAMME, P., ECTOR, B., DEBONNAIRE, P., VAN DE BORNE, P., LEROY, J., SCHROE, H., VRANCKX, P., ELEGEERT, I., HOFFER, E., DUJARDIN, K., INDIO DO BRASIL, C., PRECOMA, D., ABRANTES, J. A., MANENTI, E., REIS, G., SARAIVA, J., MAIA, L., HERNANDES, M., ROSSI, P., ROSSI DOS SANTOS, F., ZIMMERMANN, S. L., RECH, R., ABIB JR, E., LEAES, P., BOTELHO, R., DUTRA, O., SOUZA, W., BRAILE, M., IZUKAWA, N., NICOLAU, J. C., TANAJURA, L. F., SERRANO JUNIOR, C. V., MINELLI, C., NASI, L. A., OLIVEIRA, L., DE CARVALHO CANTARELLI, M. J., TYTUS, R., PANDEY, S., LONN, E., CHA, J., VIZEL, S., BABAPULLE, M., LAMY, A., SAUNDERS, K., BERLINGIERI, J., KIAII, B., BHARGAVA, R., MEHTA, P., HILL, L., FELL, D., LAM, A., AL-QOOFI, F., BROWN, C., PETRELLA, R., RICCI, J. A., GLANZ, A., NOISEUX, N., BAINEY, K., MERALI, F., HEFFERNAN, M., DELLA SIEGA, A., DAGENAIS, G. R., DAGENAIS, F., BRULOTTE, S., NGUYEN, M., HARTLEIB, M., GUZMAN, R., BOURGEOIS, R., RUPKA, D., KHAYKIN, Y., GOSSELIN, G., HUYNH, T., PILON, C., CAMPEAU, J., PICHETTE, F., DIAZ, A., JOHNSTON, J., SHUKLE, P., HIRSCH, G., RHEAULT, P., CZARNECKI, W., ROY, A., NAWAZ, S., FREMES, S., SHUKLA, D., JANO, G., COBOS, J. L., CORBALAN, R., MEDINA, M., NAHUELPAN, L., RAFFO, C., PEREZ, L., POTTHOFF, S., STOCKINS, B., SEPULVEDA, P., PINCETTI, C., VEJAR, M., TIAN, H., WU, X., KE, Y., JIA, K., YIN, P., WANG, Z., YU, L., WU, S., WU, Z., LIU, S. W., BAI, X. J., ZHENG, Y., YANG, P., YANG, Y. M., ZHANG, J., GE, J., CHEN, X. P., LI, J., HU, T. H., ZHANG, R., ZHENG, Z., CHEN, X., TAO, L., LI, J., HUANG, W., FU, G., LI, C., DONG, Y., WANG, C., ZHOU, X., KONG, Y., SOTOMAYOR, A., ACCINI MENDOZA, J. L., CASTILLO, H., URINA, M., AROCA, G., PEREZ, M., MOLINA DE SALAZAR, D. I., SANCHEZ VALLEJO, G., FERNANDO, M. J., GARCIA, H., GARCIA, L. H., ARCOS, E., GOMEZ, J., CUERVO MILLAN, F., TRUJILLO DADA, F. A., VESGA, B., MORENO SILGADO, G. A., ZIDKOVA, E., LUBANDA, J.-C., KALETOVA, M., KRYZA, R., MARCINEK, G., RICHTER, M., SPINAR, J., MATUSKA, J., TESAK, M., MOTOVSKA, Z., BRANNY, M., MALY, J., MALY, M., WIENDL, M., FOLTYNOVA CAISOVA, L., SLABY, J., VOJTISEK, P., PIRK, J., SPINAROVA, L., BENESOVA, M., CANADYOVA, J., HOMZA, M., FLORIAN, J., POLASEK, R., COUFAL, Z., SKALNIKOVA, V., BRAT, R., BRTKO, M., JANSKY, P., LINDNER, J., MARCIAN, P., STRAKA, Z., TRETINA, M., DUARTE, Y. C., POW CHON LONG, F., SANCHEZ, M., LOPEZ, J., PERUGACHI, C., MARMOL, R., TRUJILLO, F., TERAN, P., TUOMILEHTO, J., TUOMILEHTO, H., TUOMINEN, M.-L., TUOMILEHTO, H., KANTOLA, I., STEG, G., ABOYANS, V., LECLERCQ, F., FERRARI, E., BOCCARA, F., MESSAS, E., MISMETTI, P., SEVESTRE, M. A., CAYLA, G., MOTREFF, P., STOERK, S., DUENGEN, H.-D., STELLBRINK, C., GUEROCAK, O., KADEL, C., BRAUN-DULLAEUS, R., JESERICH, M., OPITZ, C., VOEHRINGER, H.-F., APPEL, K.-F., WINKELMANN, B., DORSEL, T., NIKOL, S., DARIUS, H., RANFT, J., SCHELLONG, S., JUNGMAIR, W., DAVIERWALA, P., VORPAHL, M., BAJNOK, L., LASZLO, Z., NOORI, E., VERESS, G., VERTES, A., ZSARY, A., KIS, E., KORANYI, L., BAKAI, J., BODA, Z., POOR, F., JARAI, Z., KEMENY, V., BARTON, J., MCADAM, B., MURPHY, A., CREAN, P., MAHON, N., CURTIN, R., MACNEILL, B., DINNEEN, S., HALABI, M., ZIMLICHMAN, R., ZELTSER, D., TURGEMAN, Y., KLAINMAN, E., LEWIS, B., KATZ, A., ATAR, S., ZIMLICHMAN, R., NIKOLSKY, E., BOSI, S., NALDI, M., FAGGIANO, P., ROBBA, D., MOS, L., SINAGRA, G., COSMI, F., OLTRONA VISCONTI, L., CARMINE, D. M., DI PASQUALE, G., DI BIASE, M., MANDORLA, S., BERNARDINANGELI, M., PICCINNI, G. C., GULIZIA, M. M., GALVANI, M., VENTURI, F., MOROCUTTI, G., BALDIN, M. G., OLIVIERI, C., PERNA, G. P., CIRRINCIONE, V., KANNO, T., DAIDA, H., OZAKI, Y., MIYAMOTO, N., HIGASHIUE, S., DOMAE, H., HOSOKAWA, S., KOBAYASHI, H., KURAMOCHI, T., FUJII, K., MIZUTOMI, K., SAKU, K., KIMURA, K., HIGUCHI, Y., ABE, M., OKUDA, H., NODA, T., MITA, T., HIRAYAMA, A., ONAKA, H., INOKO, M., HIROKAMI, M., OKUBO, M., AKATSUKA, Y., IMAMAKI, M., KAMIYA, H., MANITA, M., HIMI, T., UENO, H., HISAMATSU, Y., AKO, J., NISHINO, Y., KAWAKAMI, H., YAMADA, Y., KORETSUNE, Y., YAMADA, T., YOSHIDA, T., SHIMOMURA, H., KINOSHITA, N., TAKAHASHI, A., YUSOFF, K., WAN AHMAD, W. A., ABU HASSAN, M. R., KASIM, S., ABDUL RAHIM, A. A., MOHD ZAMRIN, D., MACHIDA, M., HIGASHINO, Y., UTSU, N., NAKANO, A., NAKAMURA, S., HASHIMOTO, T., ANDO, K., SAKAMOTO, T., PRINS, F. J., LOK, D., MILHOUS, J. G.-J., VIERGEVER, E., WILLEMS, F., SWART, H., ALINGS, M., BREEDVELD, R., DE VRIES, K.-J., VAN DER BORGH, R., OEI, F., ZOET-NUGTEREN, S., KRAGTEN, H., HERRMAN, J. P., VAN BERGEN, P., GOSSELINK, M., HOEKSTRA, E., ZEGERS, E., RONNER, E., DEN HARTOG, F., BARTELS, G., NIEROP, P., VAN DER ZWAAN, C., VAN ECK, J., VAN GORSELEN, E., GROENEMEIJER, B., HOOGSLAG, P., DE GROOT, M. R., LOYOLA, A., SULIT, D. J., REY, N., ABOLA, M. T., MORALES, D., PALOMARES, E., ABAT, M. E., ROGELIO, G., CHUA, P., DEL PILAR, J. C., ALCARAZ, J. D., EBO, G., TIRADOR, L., CRUZ, J., ANONUEVO, J., PITARGUE, A., JANION, M., GUZIK, T., GAJOS, G., ZABOWKA, M., RYNKIEWICZ, A., BRONCEL, M., SZUBA, A., CZARNECKA, D., MAGA, P., STRAZHESKO, I., VASYUK, Y., SIZOVA, Z., POZDNYAKOV, Y., BARBARASH, O., VOEVODA, M., POPONINA, T., REPIN, A., OSIPOVA, I., EFREMUSHKINA, A., NOVIKOVA, N., AVERKOV, O., ZATEYSHCHIKOV, D., VERTKIN, A., AUSHEVA, A., COMMERFORD, P., SEEDAT, S., VAN ZYL, L., ENGELBRECHT, J., MAKOTOKO, E. M., PRETORIUS, C. E., MOHAMED, Z., HORAK, A., MABIN, T., KLUG, E., BAE, J.-H., KIM, C., KIM, C.-J., KIM, D.-S., KIM, Y. J., JOO, S., HA, J.-W., PARK, C. S., KIM, J. Y., KIM, Y.-K., JARNERT, C., MOOE, T., DELLBORG, M., TORSTENSSON, I., ALBERTSSON, P., JOHANSSON, L., AL-KHALILI, F., ALMROTH, H., ANDERSSON, T., PANTEV, E., TENGMARK, B.-O., LIU, B., RASMANIS, G., WAHLGREN, C.-M., MOCCETTI, T., PARKHOMENKO, A., TSELUYKO, V., VOLKOV, V., KOVAL, O., KONONENKO, L., PROKHOROV, O., VDOVYCHENKO, V., BAZYLEVYCH, A., RUDENKO, L., VIZIR, V., KARPENKO, O., MALYNOVSKY, Y., KOVAL, V., STOROZHUK, B., COTTON, J., VENKATARAMAN, A., MORIARTY, A., CONNOLLY, D., DAVEY, P., SENIOR, R., BIRDI, I., CALVERT, J., DONNELLY, P., TREVELYAN, J., CARTER, J., PEACE, A., AUSTIN, D., KUKREJA, N., HILTON, T., SRIVASTAVA, S., WALSH, R., FIELDS, R., HAKAS, J., PORTNAY, E., GOGIA, H., SALACATA, A., HUNTER, J. J., BACHARACH, J. M., SHAMMAS, N., SURESH, D., SCHNEIDER, R., GURBEL, P., BANERJEE, S., GRENA, P., BEDWELL, N., SLOAN, S., LUPOVITCH, S., SONI, A., GIBSON, K., SANGRIGOLI, R., MEHTA, R., I-HSUAN TSAI, P., GILLESPIE, E., DEMPSEY, S., HAMROFF, G., BLACK, R., LADER, E., KOSTIS, J. B., BITTNER, V., MCGUINN, W., BRANCH, K., MALHOTRA, V., MICHAELSON, S., VACANTE, M., MCCORMICK, M., ARIMIE, R., CAMP, A., DAGHER, G., KOSHY, N. M., THEW, S., COSTELLO, F., HEIMAN, M., CHILTON, R., MORAN, M., ADLER, F., COMEROTA, A., SEIWERT, A., FRENCH, W., SEROTA, H., HARRISON, R., BAKAEEN, F., OMER, S., CHANDRA, L., WHELAN, A., BOYLE, A., ROBERTS-THOMSON, P., ROGERS, J., CARROLL, P., COLQUHOUN, D., SHAW, J., BLOMBERY, P., AMERENA, J., HII, C., ROYSE, A., SINGH, B., SELVANAYAGAM, J., JANSEN, S., LO, W., HAMMETT, C., POULTER, R., NARASIMHAN, S., WIGGERS, H., NIELSEN, H., GISLASON, G., KOBER, L., HOULIND, K., BOENELYKKE SOERENSEN, V., DIXEN, U., REFSGAARD, J., ZEUTHEN, E., SOEGAARD, P., HRANAI, M., GASPAR, L., PELLA, D., HATALOVA, K., DROZDAKOVA, E., COMAN, I., DIMULESCU, D., VINEREANU, D., CINTEZA, M., SINESCU, C., ARSENESCU, C., BENEDEK, I., BOBESCU, E., DOBREANU, D., GAITA, D., IANCU, A., ILIESIU, A., LIGHEZAN, D., PETRESCU, L., PIRVU, O., TEODORESCU, I., TESLOIANU, D., VINTILA, M. M., & CHIONCEL, O.
- Affiliations
- Population Health Research Institute (CA)
- Charles University (CZ)
- Thrombosis Research Institute (GB)
- Semmelweis University (HU)
- Associazione Nazionale Medici Cardiologi Ospedalieri (IT)
- University of Würzburg (DE)
- Fu Wai Hospital (CN)
- Ollscoil na Gaillimhe – University of Galway (IE)
- University of Edinburgh (GB)
- Brigham and Women's Hospital (US)
- Bayer (Germany) (DE)
- Monash University (AU)
- KU Leuven (BE)
- Bayer (United States) (US)
- Universidad Autónoma de Madrid (ES)
- Estudios Clínicos Latinoamérica (AR)
- Hamilton General Hospital (CA)
- McMaster University (CA)
- University of Washington (US)
- Université de Versailles Saint-Quentin-en-Yvelines (FR)
- Centre Hospitalier Universitaire de Montpellier (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Paris Cardiovascular Research Center (FR)
- University of Cape Town (ZA)
- Centre Hospitalier Universitaire de Nîmes (FR)
- Centre Hospitalier Universitaire de Clermont-Ferrand (FR)
- Werkgroep Cardiologische centra Nederland (NL)
- University of Debrecen (HU)
- University of Trieste (IT)
- Sahlgrenska University Hospital (SE)
- Karolinska Institutet (SE)
- Hôpital Universitaire Dupuytren (FR)
- Istituto Cardiocentro Ticino (CH)
- Danylo Halytsky Lviv National Medical University (UA)
- Foscal Hospital (CO)
- National Research Center for Preventive Medicine (RU)
- Carol Davila University of Medicine and Pharmacy (RO)
- Institutul de Urgenţă pentru Boli Cardiovasculare "Prof.Dr. C.C. Iliescu" (RO)
- Corresponding author
- Anand, Sonia S
- ORCID
- Anand, Sonia S
- Bosch, Jackie
- Eikelboom, John W
- Connolly, Stuart J
- Kakkar, Ajay K
- Keltai, Katalin
- Maggioni, Aldo P
- Störk, Stefan
- Zhu, Jun
- O'Donnell, Martin
- Fox, Keith A A
- Bhatt, Deepak L
- Misselwitz, Frank
- Vanassche, Thomas
- Leong, Darryl P
- Bangdiwala, Shrikant I
- Hart, Robert G
- Yusuf, Salim
- SCHYGIEL, PABLO OMAR
- COSTABEL, JUAN PABLO
- MACIN, STELLA MARIS
- GRINFELD, DIEGO
- VERHAMME, PETER
- DEBONNAIRE, PHILIPPE
- VRANCKX, PASCAL
- ELEGEERT, IVAN
- HOFFER, ETIENNE
- MANENTI, EULER
- REIS, GILMAR
- HERNANDES, MAURO
- TANAJURA, LUIZ FERNANDO
- TYTUS, RICHARD
- LONN, EVA
- LAMY, ANDRE
- NOISEUX, NICOLAS
- BAINEY, KEVIN
- DAGENAIS, GILLES R
- NGUYEN, MICHEL
- GUZMAN, RANDOLPH
- KHAYKIN, YAARIV
- GOSSELIN, GILBERT
- HUYNH, THAO
- ROY, ANNIE
- JIA, KAIYING
- WU, SHULIN
- ZHANG, JIWEI
- GE, JUNBO
- FU, GUOSHENG
- VESGA, BORIS
- LUBANDA, JEAN-CLAUDE
- MOTOVSKA, ZUZANA
- BRANNY, MARIAN
- HOMZA, MIROSLAV
- BRTKO, MIROSLAV
- DUARTE, YAN CARLOS
- SANCHEZ, MAYRA
- TUOMILEHTO, JAAKKO
- KANTOLA, ILKKA
- LECLERCQ, FLORENCE
- BOCCARA, FRANCK
- MESSAS, EMMANUEL
- SEVESTRE, MARIE ANTOINETTE
- CAYLA, GUILLAUME
- MOTREFF, PASCAL
- STELLBRINK, CHRISTOPH
- OPITZ, CHRISTIAN
- NIKOL, SIGRID
- SCHELLONG, SEBASTIAN
- DAVIERWALA, PIROZE
- VORPAHL, MARC
- KORANYI, LASZLO
- MURPHY, ANDREW
- MAHON, NIALL
- HALABI, MAJDI
- ZELTSER, DAVID
- KATZ, AMOS
- ATAR, SHAUL
- FAGGIANO, POMPILIO
- ROBBA, DEBORA
- MOS, LUCIO
- SINAGRA, GIANFRANCO
- GULIZIA, MICHELE MASSIMO
- GALVANI, MARCELLO
- PERNA, GIAN PIERO
- OZAKI, YUKIO
- HIGASHIUE, SHINICHI
- HOSOKAWA, SHINOBU
- FUJII, KENSHI
- KIMURA, KAZUO
- HIGUCHI, YOSHIHARU
- NODA, TOSHIYUKI
- HIRAYAMA, ATSUSHI
- INOKO, MORIAKI
- MANITA, MAMORU
- AKO, JUNYA
- YOSHIDA, TETSURO
- SHIMOMURA, HIDEKI
- KINOSHITA, NORIYUKI
- TAKAHASHI, AKIHIKO
- YUSOFF, KHALID
- KASIM, SAZZLI
- NAKANO, AKIHIKO
- NAKAMURA, SHIGERU
- SAKAMOTO, TOMOHIRO
- RONNER, EELKO
- BARTELS, GERARD
- ABOLA, MARIA TERESA
- ABAT, MARC EVANS
- JANION, MARIANNA
- GUZIK, TOMASZ
- GAJOS, GRZEGORZ
- RYNKIEWICZ, ANDRZEJ
- BRONCEL, MARLENA
- SZUBA, ANDRZEJ
- CZARNECKA, DANUTA
- SIZOVA, ZHANNA
- VOEVODA, MIKHAIL
- REPIN, ALEXEY
- EFREMUSHKINA, ANNA
- ZATEYSHCHIKOV, DMITRY
- BAE, JANG-HO
- HA, JONG-WON
- MOOE, THOMAS
- DELLBORG, MIKAEL
- ALBERTSSON, PER
- WAHLGREN, CARL-MAGNUS
- MOCCETTI, TIZIANO
- PARKHOMENKO, ALEXANDER
- TSELUYKO, VIRA
- KOVAL, OLENA
- BAZYLEVYCH, ANDRIY
- KARPENKO, OLEKSANDR
- MALYNOVSKY, YAROSLAV
- COTTON, JAMES
- CONNOLLY, DEREK
- DAVEY, PATRICK
- SENIOR, ROXY
- PEACE, AARON
- AUSTIN, DAVID
- SRIVASTAVA, SUNNY
- SHAMMAS, NICOLAS
- GURBEL, PAUL
- BANERJEE, SUBHASH
- MEHTA, RAJENDRA
- GILLESPIE, EVE
- HAMROFF, GLENN
- LADER, ELLIS
- KOSTIS, JOHN B.
- BITTNER, VERA
- CHILTON, ROBERT
- COMEROTA, ANTHONY
- BAKAEEN, FAISAL
- AMERENA, JOHN
- ROYSE, ALISTAIR
- SELVANAYAGAM, JOSEPH
- JANSEN, SHIRLEY
- HAMMETT, CHRISTOPHER
- POULTER, ROHAN
- NARASIMHAN, SESHASAYEE
- GISLASON, GUNNAR
- HOULIND, KIM
- DIXEN, ULRIK
- REFSGAARD, JENS
- PELLA, DANIEL
- SINESCU, CRINA
- BENEDEK, IMRE
- BOBESCU, ELENA
- DOBREANU, DAN
- IANCU, ADRIAN
- LIGHEZAN, DANIEL
- PETRESCU, LUCIAN
- TESLOIANU, DAN
- CHIONCEL, OVIDIU
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2018-01
- Volume
- 391
- Issue
- 10117
- Pages
- 219-229
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4229536675
- Semantic Scholar
- af705d340539758c05004e20b5429bd9700e2fc2
- Cited by
- 879
- References
- 30
- Citations by year
- 2026: 52 · 2025: 62 · 2024: 74 · 2023: 99 · 2022: 109 · 2021: 139 · 2020: 152 · 2019: 112 · 2018: 74
- FWCI
- 72.81
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Lancet (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Arrow@dit (Dublin Institute of Technology) (submittedVersion)
- HAL (submittedVersion)
- ARAN (University of Galway Research Repository) (Ollscoil na Gaillimhe – University of Galway) (submittedVersion, cc-by-nc-nd)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion, cc-by-sa)
- Lirias (submittedVersion)
- Scopus (Elsevier) (submittedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion, cc-by-nc-nd)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Surgery › Peripheral Artery Disease Management
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Keywords
- rivaroxaban, aspirin, peripheral arterial disease, carotid artery disease, coronary artery disease, major adverse limb events, major amputation, cardiovascular mortality, myocardial infarction, stroke, antiplatelet therapy, direct oral anticoagulants, ankle-brachial index, intermittent claudication, asymptomatic carotid stenosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review